The Effects and Safety of Vasopressin Receptor Agonists in Patients with Septic Shock: a Meta-analysis and Trial Sequential Analysis

Overview

Journal Crit Care

Specialty Critical Care

Date 2019 Mar 16

PMID 30871607

Citations 17

Authors

Libing Jiang

Yi Sheng

Xia Feng

Jing Wu

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to evaluate the effects and safety of vasopressin receptor agonists in patients with septic shock.

Methods: PubMed, EMBASE, and Cochrane library were searched for randomized controlled trials evaluating the effects of vasopressin receptor agonists in septic shock patients. Two reviewers performed literature selection, data extraction, and quality evaluation independently. The primary outcome was mortality. And secondary outcomes included intensive care unit (ICU) length of stay, duration of mechanical ventilation, and incidence of adverse events. In addition, a trial sequential analysis (TSA) was performed.

Results: Twenty studies were eligible for meta-analysis. The results showed vasopressin receptor agonists use was associated with reduced mortality (relative risk (RR) 0.92; 95% confidence interval (CI) 0.84 to 0.99; I = 0%). Nevertheless, they had no significant effects on ICU length of stay (mean deviation (MD) - 0.08, 95% CI, - 0.68 to 0.52, I = 0%) and duration of mechanical ventilation (MD - 0.58, 95% CI - 1.47 to 0.31, I = 57%). Additionally, there was no significant difference in total adverse events between two groups (RR 1.28, 95% CI 0.87 to 1.90, I = 57%), but vasopressin receptor agonists administration could significantly increase the risk of digital ischemia (RR 4.85, 95% CI 2.81 to 8.39, I = 26%). Finally, there was no statistical difference of cardiovascular events (RR 0.91, 95% CI 0.53 to 1.57, I = 1%), arrhythmia (0.77, 95% CI 0.48 to 1.23, I = 23%), mesenteric ischemia (0.83, 95% CI 0.44 to 1.55, I = 0%), diarrhea (2.47, 95% CI 0.77 to 7.96, I = 49%), cerebrovascular events (1.36, 95% CI 0.18 to 10.54, I = 0%), and hyponatremia (1.47, 95% CI 0.84 to 2.55, I = 0%) between two groups. Egger's test showed there was no significant publication bias among studies (P = 0.36).

Conclusions: The use of vasopressin might result in reduced mortality in patients with septic shock. An increased risk of digital ischemia must be taken into account.

Citing Articles

Management of vasoplegic shock.

Mistry R, Winearls J BJA Educ. 2025; 25(2):65-73.

PMID: 39897429 PMC: 11785552. DOI: 10.1016/j.bjae.2024.10.004.

Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.

Kotani Y, Belletti A, DAmico F, Bonaccorso A, Wieruszewski P, Fujii T Crit Care. 2024; 28(1):439.

PMID: 39736782 PMC: 11686893. DOI: 10.1186/s13054-024-05212-7.

Advancements in Trauma-Induced Acute Kidney Injury: Diagnostic and Therapeutic Innovations.

Lassola S, Cundari F, Marini G, Corradi F, De Rosa S Life (Basel). 2024; 14(8).

PMID: 39202747 PMC: 11355063. DOI: 10.3390/life14081005.

Treatment of Acute Kidney Injury: A Review of Current Approaches and Emerging Innovations.

Tamargo C, Hanouneh M, Cervantes C J Clin Med. 2024; 13(9).

PMID: 38730983 PMC: 11084889. DOI: 10.3390/jcm13092455.

Effects of Early Initiation of Polymyxin B Hemoperfusion Therapy in Patients with Cancer with Refractory Septic Shock.

Lee J, Han W, Im H, Kim J J Clin Med. 2024; 13(4).

PMID: 38398322 PMC: 10889516. DOI: 10.3390/jcm13041009.

References

McIntyre W, Um K, Alhazzani W, Lengyel A, Hajjar L, Gordon A . Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. JAMA. 2018; 319(18):1889-1900. PMC: 6583502. DOI: 10.1001/jama.2018.4528. View

Boyd J, Forbes J, Nakada T, Walley K, Russell J . Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2010; 39(2):259-65. DOI: 10.1097/CCM.0b013e3181feeb15. View

Gordon A, Russell J, Walley K, Singer J, Ayers D, Storms M . The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med. 2009; 36(1):83-91. DOI: 10.1007/s00134-009-1687-x. View

Klinzing S, Simon M, Reinhart K, Bredle D, Meier-Hellmann A . High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med. 2003; 31(11):2646-50. DOI: 10.1097/01.CCM.0000094260.05266.F4. View

Gordon A, Mason A, Thirunavukkarasu N, Perkins G, Cecconi M, Cepkova M . Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA. 2016; 316(5):509-18. DOI: 10.1001/jama.2016.10485. View

Nagendran M, Maruthappu M, Gordon A, Gurusamy K . Comparative safety and efficacy of vasopressors for mortality in septic shock: A network meta-analysis. J Intensive Care Soc. 2017; 17(2):136-145. PMC: 5606402. DOI: 10.1177/1751143715620203. View

Landry D, Levin H, Gallant E, Ashton Jr R, Seo S, DAlessandro D . Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997; 95(5):1122-5. DOI: 10.1161/01.cir.95.5.1122. View

Gordon A, Wang N, Walley K, Ashby D, Russell J . The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest. 2012; 142(3):593-605. DOI: 10.1378/chest.11-2604. View

Chen Z, Zhou P, Lu Y, Yang C . [Comparison of effect of norepinephrine and terlipressin on patients with ARDS combined with septic shock: a prospective single-blind randomized controlled trial]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017; 29(2):111-116. DOI: 10.3760/cma.j.issn.2095-4352.2017.02.004. View

10.

Albanese J, Leone M, Delmas A, Martin C . Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med. 2005; 33(9):1897-902. DOI: 10.1097/01.ccm.0000178182.37639.d6. View

11.

Yang G, Li T, Xu J, Liu L . PKC plays an important mediated effect in arginine vasopressin induced restoration of vascular responsiveness and calcium sensitization following hemorrhagic shock in rats. Eur J Pharmacol. 2009; 628(1-3):148-54. DOI: 10.1016/j.ejphar.2009.11.040. View

12.

Sprung C, Annane D, Keh D, Moreno R, Singer M, Freivogel K . Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008; 358(2):111-24. DOI: 10.1056/NEJMoa071366. View

13.

. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study. Intensive Care Med. 2016; 42(12):1980-1989. DOI: 10.1007/s00134-016-4504-3. View

14.

Morelli A, Ertmer C, Pietropaoli P, Westphal M . Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock. Expert Opin Pharmacother. 2009; 10(15):2569-75. DOI: 10.1517/14656560903257808. View

15.

Yang G, Liu L, Xu J, Li T . Effect of arginine vasopressin on vascular reactivity and calcium sensitivity after hemorrhagic shock in rats and its relationship to Rho-kinase. J Trauma. 2006; 61(6):1336-42. DOI: 10.1097/01.ta.0000197928.99745.22. View

16.

Hammond D, Cullen J, Painter J, McCain K, Clem O, Brotherton A . Efficacy and Safety of the Early Addition of Vasopressin to Norepinephrine in Septic Shock. J Intensive Care Med. 2017; 34(11-12):910-916. DOI: 10.1177/0885066617725255. View

17.

Han X, Sun H, Huang X, Zhang S, Wang Y, Ren K . [A clinical study of pituitrin versus norepinephrine in the treatment of patients with septic shock]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012; 24(1):33-7. View

18.

Choudhury A, Kedarisetty C, Vashishtha C, Saini D, Kumar S, Maiwall R . A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2016; 37(4):552-561. DOI: 10.1111/liv.13252. View

19.

Lange M, Ertmer C, Westphal M . Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med. 2007; 34(5):821-32. DOI: 10.1007/s00134-007-0946-y. View

20.

Kopel T, Losser M, Faivre V, Payen D . Systemic and hepatosplanchnic macro- and microcirculatory dose response to arginine vasopressin in endotoxic rabbits. Intensive Care Med. 2008; 34(7):1313-20. DOI: 10.1007/s00134-008-1058-z. View